LUCID DIAGNOSTICS INC (LUCD)
Health Care · NASDAQ
Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at risk.
What LUCID DIAGNOSTICS INC does
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company focused on detecting esophageal adenocarcinoma (EAC) and Barrett's esophagus in patients with chronic gastroesophageal reflux disease (GERD). The company's flagship product, EsoGuard, is a bisulfite-converted targeted next-generation sequencing DNA assay that detects methylation patterns in esophageal cells collected via the EsoCheck swallowable cell collection device. EsoGuard and EsoCheck are designed to enable widespread screening of at-risk GERD patients to prevent EAC deaths through early detection of esophageal precancer.
Themes: ["esophageal cancer screening"]
Fundamentals
- Price$0.99 as of 2026-07-09 close
- Market cap$201M as of 2026-07-10
- 1-year return-8.7% as of 2026-07-09 close
- Net margin-876.7% as of 2026-07-10
- Gross margin-31.4% as of 2026-07-10
- ROE-370.2% as of 2026-07-10
- Debt / equity6.30 as of 2026-07-10
- Revenue growth (YoY)+23.0% as of 2026-07-10
- Revenue CAGR (3y)+105.6% SEC XBRL
- Beta1.14 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative 876.72% net margin; high operating expenses ($13.4M in Q1 2026) against minimal revenue ($1.3M), with accumulated deficit of $298M as of March 2026"]
Competitors & peers
- Exact Sciences (EXAS) - broad oncology screening/diagnostics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.